Wonderful Review | The Symposium on R & D and Industrialization of Veterinary mRNA Vaccines in Xiamen Successfully Concluded. Grateful for all the encounters, looking forward to meeting again!

The mRNA Veterinary Vaccine Development and Industrialization Symposium Concludes Successfully.

The 10th China Veterinary Drug Exhibition, held on June 18th at the Xiamen International Conference and Exhibition Center, concluded successfully with a concurrent symposium on the research and industrialization of veterinary mRNA vaccines! The forum, spearheaded by our company, aimed to establish a platform for exchanging ideas, sharing experiences, and fostering collaboration.

This year's forum focused on "Research and Industrialization of Veterinary mRNA Vaccines," with an emphasis on addressing critical and unique technical challenges in the research and application of veterinary mRNA vaccines. The goal was to promote innovation in the development of veterinary biological products and to precisely align with market demands.

The symposium commenced with a video presentation by Researcher Liu Yebing, Director of the National Classical Swine Fever Reference Laboratory and the China Institute of Veterinary Drug Control (Veterinary Drug Evaluation Center of the Ministry of Agriculture and Rural Affairs). His presentation, titled "Current Status and Development Prospects of Animal mRNA Vaccine Research," provided an in-depth and insightful discussion covering "mRNA technology and vaccine development, key points of process and quality control involved in animal mRNA vaccine research and development practice, issues faced by animal mRNA vaccine industrialization and GMP production workshops, development and prospects." Using the development of the classical swine fever mRNA vaccine as a case study, he offered the industry a comprehensive understanding of mRNA technology and vaccine development, clarified key points in research and development practice, and pointed out the direction of industrialization and the problems to be solved.

Dr. Li Bin, Director of the Veterinary Institute of the Jiangsu Academy of Agricultural Sciences, presented on "The Prevalence of Porcine Diarrhea Viruses and the Progress of mRNA Vaccine Research." His presentation comprehensively covered "The Current Status of Outbreaks of Diarrhea in Piglets, the Use of Porcine Viral Diarrhea Vaccines, and the Research and Development Progress of Porcine Viral Diarrhea mRNA Vaccines." Dr. Li highlighted that the mortality rate of piglets within 10 days of age due to diarrhea viruses can reach up to 100%. Currently, there are numerous pathogens and diverse genotypes causing diarrhea in piglets, coupled with poor immunogenicity and lengthy development cycles. Therefore, there is an urgent need to develop novel vaccines with high immune efficacy, capable of multivalent and broad-spectrum protection. Dr. Li shared the collaborative research between the animal diarrhea disease prevention and control team of the Veterinary Institute of the Jiangsu Academy of Agricultural Sciences and Suzhou Huiliao Biomedical Technology Co., Ltd. on the development of PEDV mRNA vaccines, PDCoV mRNA vaccines, and porcine rotavirus mRNA vaccines, as well as the passive protection provided by vaccinated sows to piglets. He also discussed the antibody and cellular immune responses of vaccinated sows and piglets, and the protective effects of passive immunization challenge studies. This research provides insights and strategies for the future development and industrialization of porcine diarrhea virus mRNA vaccines, emphasizing the rapid, efficient, and platform advantages of mRNA vaccine technology. Furthermore, he noted the increasingly Improve the industrial chain and broad application prospects.

Professor Zhao Lixiang, CTO of Suzhou HuiLiao Biomedical Technology Co., Ltd. and a faculty member of the School of Basic Medical Sciences and Biological Sciences at Soochow University, delivered a presentation titled "Design and Delivery System of Veterinary mRNA Vaccines". Professor Zhao elaborated on three aspects: "Background of mRNA Vaccines, mRNA Delivery Systems, and Design Optimization of mRNA Vaccines". He pointed out that the artificial synthesis of mRNA undergoes a challenging process to translate into proteins in the body, and the delivery system, as the "bucket", determines the "water" (mRNA) quantity. Therefore, the delivery system is crucial in the development of mRNA vaccines. HuiLiao Biotech's self-developed mRNA delivery system - human-targeted delivery, based on the Cell-like System (CLS) delivery carrier, adopts a CLS structure that mimics the protein-phospholipid bilayer in the cell membrane for efficient transmembrane delivery, featuring high delivery efficiency. Additionally, the self-developed mRNA vaccine delivery system for infectious disease vaccines offers excellent cellular and humoral responses and safety performance. Currently, HuiLiao Biotech is developing multiple vaccine pipelines including those for swine PEDV and PRRS, as well as cat FIP and dog multivalent vaccines, with plans to submit some vaccine varieties for GCP clinical trials in 2024.

During the forum, several key figures presented their insights. These included Manager Meng Xia from the diamond support unit, Nanjing Vazyme Biotech Co., Ltd.; Dr. Zhou Lin from the platinum support unit, Suzhou Genewiz Biotechnology Co., Ltd.; General Manager Wu Gang from Maina (Shanghai) Instruments Technology Co., Ltd.; and Manager Li Yunfeng from Hangzhou Kebait Filter Materials Co., Ltd. They discussed various aspects of veterinary mRNA vaccine development, including upstream raw materials, mRNA vaccine production technology, processes, and equipment.

The experts and scholars engaged in lively discussions throughout the conference, with a dynamic atmosphere. They shared suggestions based on their respective work experiences. This forum not only enhanced communication and collaboration within the industry but also injected fresh vitality into the innovation and development of the veterinary mRNA vaccine sector.

--------------------------------------

1、The conference venue for veterinary pharmaceuticals.

The 10th China Veterinary Drug Exhibition, held at the Xiamen International Conference & Exhibition Center from June 18th to 19th, 2024, was a resounding success. Centered around the theme of "Developing New Quality Productive Forces, Stimulating New Industrial Momentum," this year's exhibition served as the premier annual event for China's veterinary drug industry. It provided a vital platform for the exchange of new policies, concepts, knowledge, and technologies. Furthermore, it facilitated technology exchange, the translation of research findings into practical applications, and international collaborations. As a comprehensive platform for product showcasing, technology promotion, and business negotiations, the exhibition offered invaluable opportunities for communication and advancement within the veterinary drug sector.

2、The exhibition hall.

At the 10th China Veterinary Drug Exhibition, Suzhou Industrial Park Bio-Industry Development Co., Ltd. led a delegation of 13 enterprises. Suzhou Hylife was honored to be among the invited participants. Through this exhibition, we engaged in in-depth exchanges with industry colleagues and showcased our cutting-edge products and technologies to a wide audience of users and partners. This event has undoubtedly laid a solid foundation for our future development, providing us with valuable opportunities and broad support.

#Conference Summary#

In an era of rapid technological innovation, the veterinary mRNA vaccine sector stands at a new developmental juncture. We are confident that through continuous technological innovation and industry dialogue, the veterinary mRNA vaccine industry will embrace a broader horizon of development, making significant contributions to animal health and the advancement of human health initiatives. The emergence of more outstanding enterprises and products will collectively propel the progress and prosperity of the veterinary vaccine industry.

The successful hosting of this veterinary mRNA vaccine forum has not only injected fresh vitality into the development of the veterinary mRNA vaccine industry but also provided participating enterprises with a crucial platform to showcase their strengths and foster collaboration. As the host, our company will continue to contribute to the innovative development of the veterinary mRNA vaccine industry. We also look forward to collaborating with more industry colleagues to create a promising future.

Finally, we extend our gratitude to all the experts, scholars, and guests for their support and attendance, which ensured the successful conclusion of this conference! We anticipate our next gathering!

#About Suzhou Huiliao #

Suzhou Huiliao Biotechnology is a high-tech enterprise engaged in the comprehensive provision of nucleic acid drug industrialization. The company's business spans the research and production of mRNA drugs, clinical trial design, data analysis, and other areas, with a focus on the development of mRNA technology-based infectious disease vaccines, cancer vaccines, cell therapies, protein replacements, and more.